protoporphyrin ix has been researched along with Erythema in 16 studies
protoporphyrin IX: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7685
protoporphyrin : A cyclic tetrapyrrole that consists of porphyrin bearing four methyl substituents at positions 3, 8, 13 and 17, two vinyl substituents at positions 7 and 12 and two 2-carboxyethyl substituents at positions 2 and 18. The parent of the class of protoporphyrins.
Erythema: Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) photodynamic therapy (PDT) is an effective FDA-approved therapy for actinic keratosis (AK), a substantial fraction of patients (up to 25%) do not respond to treatment." | 9.20 | Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy. ( Chapman, MS; Davis, SC; Hasan, T; Kanick, SC; Maytin, EV; Pogue, BW; Sheehan, KL; Zhao, Y, 2015) |
| "To determine the impact of skin pretreatment with microneedles (MNs) on ALA- and MAL-induced protoporphyrin IX (PpIX) production, as well as MN impact on pain sensations during light exposure and erythema after PDT." | 9.14 | Microneedle pre-treatment of human skin improves 5-aminolevulininc acid (ALA)- and 5-aminolevulinic acid methyl ester (MAL)-induced PpIX production for topical photodynamic therapy without increase in pain or erythema. ( Donnelly, RF; Garland, MJ; Iani, V; Juzeniene, A; Mikolajewska, P; Moan, J; Morrow, DI; Singh, TR, 2010) |
| " Here, the ability of discrete PS fluorescence-based metrics (absolute and percent PS photobleaching and PS re-accumulation post-PDT) to predict the clinical phototoxic response (erythema) resulting from 5-aminolevulinic acid PDT was compared with discrete SOL (DSOL)-based metrics (DSOL counts pre-PDT and change in DSOL counts pre/post-PDT) in healthy human skin." | 7.80 | Photosensitizer fluorescence and singlet oxygen luminescence as dosimetric predictors of topical 5-aminolevulinic acid photodynamic therapy induced clinical erythema. ( Anbil, S; Davis, SJ; Elrington, S; Hasan, T; Kositratna, G; Lee, S; Mallidi, S; Manstein, D; Pogue, B; Schoenfeld, D, 2014) |
| "Although aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) photodynamic therapy (PDT) is an effective FDA-approved therapy for actinic keratosis (AK), a substantial fraction of patients (up to 25%) do not respond to treatment." | 5.20 | Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy. ( Chapman, MS; Davis, SC; Hasan, T; Kanick, SC; Maytin, EV; Pogue, BW; Sheehan, KL; Zhao, Y, 2015) |
| " Objective and visual erythema, protoporphyrin IX (PpIX) fluorescence and pain were evaluated." | 5.19 | Topical corticosteroid reduces inflammation without compromising the efficacy of photodynamic therapy for actinic keratoses: a randomized clinical trial. ( Petersen, B; Wiegell, SR; Wulf, HC, 2014) |
| "To determine the impact of skin pretreatment with microneedles (MNs) on ALA- and MAL-induced protoporphyrin IX (PpIX) production, as well as MN impact on pain sensations during light exposure and erythema after PDT." | 5.14 | Microneedle pre-treatment of human skin improves 5-aminolevulininc acid (ALA)- and 5-aminolevulinic acid methyl ester (MAL)-induced PpIX production for topical photodynamic therapy without increase in pain or erythema. ( Donnelly, RF; Garland, MJ; Iani, V; Juzeniene, A; Mikolajewska, P; Moan, J; Morrow, DI; Singh, TR, 2010) |
| "To evaluate the efficacy and safety of LPDL alone versus LPDL in photodynamic therapy with methylaminolevulinic acid (MAL-LPDL) for acne vulgaris." | 5.13 | Long-pulsed dye laser versus long-pulsed dye laser-assisted photodynamic therapy for acne vulgaris: A randomized controlled trial. ( Haedersdal, M; Togsverd-Bo, K; Wiegell, SR; Wulf, HC, 2008) |
| " Here, the ability of discrete PS fluorescence-based metrics (absolute and percent PS photobleaching and PS re-accumulation post-PDT) to predict the clinical phototoxic response (erythema) resulting from 5-aminolevulinic acid PDT was compared with discrete SOL (DSOL)-based metrics (DSOL counts pre-PDT and change in DSOL counts pre/post-PDT) in healthy human skin." | 3.80 | Photosensitizer fluorescence and singlet oxygen luminescence as dosimetric predictors of topical 5-aminolevulinic acid photodynamic therapy induced clinical erythema. ( Anbil, S; Davis, SJ; Elrington, S; Hasan, T; Kositratna, G; Lee, S; Mallidi, S; Manstein, D; Pogue, B; Schoenfeld, D, 2014) |
| "Photodynamic therapy (PDT) with topical 5-aminolevulinic acid (ALA) is increasingly employed for skin cancer, yet ALA dosing is crude." | 1.30 | Iontophoretic delivery of ALA provides a quantitative model for ALA pharmacokinetics and PpIX phototoxicity in human skin. ( Anderson, RR; Kollias, N; Rhodes, LE; Tsoukas, MM, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 10 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mallidi, S | 1 |
| Anbil, S | 1 |
| Lee, S | 1 |
| Manstein, D | 1 |
| Elrington, S | 1 |
| Kositratna, G | 1 |
| Schoenfeld, D | 1 |
| Pogue, B | 1 |
| Davis, SJ | 1 |
| Hasan, T | 2 |
| Petersen, B | 3 |
| Wiegell, SR | 5 |
| Wulf, HC | 7 |
| Lerche, CM | 1 |
| Fabricius, S | 1 |
| Philipsen, PA | 1 |
| Woods, JA | 1 |
| Ferguson, JS | 1 |
| Kalra, S | 1 |
| Degabriele, A | 1 |
| Gardner, J | 1 |
| Logan, P | 1 |
| Ferguson, J | 1 |
| Kanick, SC | 1 |
| Davis, SC | 1 |
| Zhao, Y | 1 |
| Sheehan, KL | 1 |
| Maytin, EV | 1 |
| Pogue, BW | 1 |
| Chapman, MS | 1 |
| Heerfordt, IM | 2 |
| Nissen, CV | 1 |
| Mikkelsen, CS | 1 |
| Mikolajewska, P | 2 |
| Iani, V | 2 |
| Juzeniene, A | 2 |
| Moan, J | 2 |
| Donnelly, RF | 1 |
| Garland, MJ | 1 |
| Morrow, DI | 1 |
| Singh, TR | 1 |
| Bissonnette, R | 1 |
| Tremblay, JF | 1 |
| Juzenas, P | 1 |
| Boushira, M | 1 |
| Lui, H | 1 |
| Choudry, K | 1 |
| Brooke, RC | 1 |
| Farrar, W | 1 |
| Rhodes, LE | 3 |
| Haedersdal, M | 1 |
| Togsverd-Bo, K | 1 |
| Tsoukas, MM | 1 |
| Anderson, RR | 1 |
| Kollias, N | 1 |
| Gerscher, S | 1 |
| Connelly, JP | 1 |
| Beijersbergen Van Henegouwen, GM | 1 |
| MacRobert, AJ | 1 |
| Watt, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Indoor Daylight Photo Dynamic Therapy (PDT) for Actinic Keratosis[NCT03805737] | 43 participants (Actual) | Interventional | 2019-11-01 | Completed | |||
| Portable Measurement of Protoporphyrin IX in the Skin[NCT04223570] | 218 participants (Anticipated) | Observational | 2022-12-01 | Enrolling by invitation | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 trials available for protoporphyrin ix and Erythema
| Article | Year |
|---|---|
Light protection of the skin after photodynamic therapy reduces inflammation: an unblinded randomized controlled study.
Topics: Aminolevulinic Acid; Drug Eruptions; Erythema; Female; Fluorescence; Humans; Keratosis, Actinic; Mal | 2014 |
Topical corticosteroid reduces inflammation without compromising the efficacy of photodynamic therapy for actinic keratoses: a randomized clinical trial.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminolevulinic Acid; Anti-Inflammatory Agents; C | 2014 |
Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
Topics: Aminolevulinic Acid; Biomarkers; Dose-Response Relationship, Drug; Erythema; Female; Humans; Keratos | 2015 |
Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
Topics: Aminolevulinic Acid; Biomarkers; Dose-Response Relationship, Drug; Erythema; Female; Humans; Keratos | 2015 |
Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
Topics: Aminolevulinic Acid; Biomarkers; Dose-Response Relationship, Drug; Erythema; Female; Humans; Keratos | 2015 |
Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.
Topics: Aminolevulinic Acid; Biomarkers; Dose-Response Relationship, Drug; Erythema; Female; Humans; Keratos | 2015 |
Pulse photodynamic therapy reduces inflammation without compromising efficacy in the treatment of multiple mild actinic keratoses of the face and scalp: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Erythema; Facial Dermatoses; Female; Fluorescence; Hum | 2016 |
Increased protoporphyrin IX accumulation does not improve the effect of photodynamic therapy for actinic keratosis: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Curettage; Drug Eruptions; Erythema; Female; Fluoresce | 2017 |
Microneedle pre-treatment of human skin improves 5-aminolevulininc acid (ALA)- and 5-aminolevulinic acid methyl ester (MAL)-induced PpIX production for topical photodynamic therapy without increase in pain or erythema.
Topics: Administration, Cutaneous; Adult; Aminolevulinic Acid; Erythema; Female; Humans; Light; Male; Needle | 2010 |
Systemic photodynamic therapy with aminolevulinic acid induces apoptosis in lesional T lymphocytes of psoriatic plaques.
Topics: Administration, Oral; Aminolevulinic Acid; Apoptosis; CD3 Complex; Epidermis; Erythema; Humans; Phot | 2002 |
The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Car | 2003 |
Long-pulsed dye laser versus long-pulsed dye laser-assisted photodynamic therapy for acne vulgaris: A randomized controlled trial.
Topics: Acne Vulgaris; Adult; Aminolevulinic Acid; Edema; Erythema; Female; Fluorescence; Humans; Laser Ther | 2008 |
7 other studies available for protoporphyrin ix and Erythema
| Article | Year |
|---|---|
Photosensitizer fluorescence and singlet oxygen luminescence as dosimetric predictors of topical 5-aminolevulinic acid photodynamic therapy induced clinical erythema.
Topics: Adult; Aminolevulinic Acid; Erythema; Female; Humans; Male; Photochemotherapy; Photosensitizing Agen | 2014 |
Correlation between treatment time, photobleaching, inflammation and pain after photodynamic therapy with methyl aminolevulinate on tape-stripped skin in healthy volunteers.
Topics: Adult; Aminolevulinic Acid; Erythema; Fluorescence; Forearm; Humans; Inflammation; Male; Middle Aged | 2015 |
The phototoxicity of vemurafenib: An investigation of clinical monochromator phototesting and in vitro phototoxicity testing.
Topics: Cell Line; Chlorpromazine; Chromatography, High Pressure Liquid; Dermatitis, Phototoxic; Dexamethaso | 2015 |
Protoporphyrin IX in the skin measured noninvasively predicts photosensitivity in patients with erythropoietic protoporphyria.
Topics: Case-Control Studies; Erythema; Female; Fluorescence; Humans; Male; Photobleaching; Protoporphyria, | 2016 |
Topical aminolaevulinic acid- and aminolaevulinic acid methyl ester-based photodynamic therapy with red and violet light: influence of wavelength on pain and erythema.
Topics: Administration, Topical; Adult; Aminolevulinic Acid; Animals; Erythema; Humans; Lasers; Mice; Mice, | 2009 |
Iontophoretic delivery of ALA provides a quantitative model for ALA pharmacokinetics and PpIX phototoxicity in human skin.
Topics: Adult; Aminolevulinic Acid; Dose-Response Relationship, Radiation; Erythema; Female; Fluorescent Dye | 1997 |
A quantitative assessment of protoporphyrin IX metabolism and phototoxicity in human skin following dose-controlled delivery of the prodrugs 5-aminolaevulinic acid and 5-aminolaevulinic acid-n-pentylester.
Topics: Adult; Aminolevulinic Acid; Dose-Response Relationship, Drug; Erythema; Female; Humans; Iontophoresi | 2001 |